Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Xlife Sciences AG's Enterprise Value is CHF265.32 Mil.
Xlife Sciences AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-31.41 Mil. Therefore, Xlife Sciences AG's EV-to-EBIT ratio for today is -8.45.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Xlife Sciences AG's Enterprise Value is CHF265.32 Mil.
Xlife Sciences AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-3.05 Mil. Therefore, Xlife Sciences AG's EV-to-EBITDA ratio for today is -86.93.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Xlife Sciences AG's Enterprise Value is CHF265.32 Mil.
Xlife Sciences AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0.28 Mil. Therefore, Xlife Sciences AG's EV-to-Revenue ratio for today is 964.81.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Xlife Sciences AG's Enterprise Value is CHF265.32 Mil.
Xlife Sciences AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-0.90 Mil. Therefore, Xlife Sciences AG's EV-to-FCF ratio for today is -293.82.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Xlife Sciences AG (XSWX:XLS) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Xlife Sciences AG's current Enterprise Value is CHF265.32 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Xlife Sciences AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-31.41 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Xlife Sciences AG's current Enterprise Value is CHF265.32 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Xlife Sciences AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-3.05 Mil.
Xlife Sciences AG's current Enterprise Value is CHF265.32 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Xlife Sciences AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0.28 Mil.
Xlife Sciences AG's current Enterprise Value is CHF265.32 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Xlife Sciences AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-0.90 Mil.
Xlife Sciences AG's current Enterprise Value is CHF265.32 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Xlife Sciences AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-0.90 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG Enterprise Value Related Terms
Xlife Sciences AG Enterprise Value Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:XLS vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, Xlife Sciences AG's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Xlife Sciences AG's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of CHF265.32 Mil mean?
Xlife Sciences AG (XSWX:XLS) has a Enterprise Value of CHF265.32 Mil as of Jun. 25, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Xlife Sciences AG and its competitors.
Is Xlife Sciences AG's Enterprise Value too high?
Xlife Sciences AG's current Enterprise Value is CHF265.32 Mil. Overall, Xlife Sciences AG has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Enterprise Value compare to VRTX and REGN?
Xlife Sciences AG's Enterprise Value of CHF265.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current Enterprise Value is CHF265.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.30, compared to a current price of CHF20.90 — trading 186.3% above its estimated fair value. The current Enterprise Value is CHF265.32 Mil. Xlife Sciences AG's overall GF Score™ is 50/100 with 13 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Enterprise Value is CHF265.32 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF20.90 is trading 186.3% above its estimated GF Value™ of CHF7.30.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
Enterprise Value: CHF265.32 Mil
GF Value™: CHF7.30 vs. price of CHF20.90 (186.3% above fair value)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
50GF Score
Get the complete analysis for XSWX:XLS
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
